Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488409 · ClinicalTrials.gov registry record · Phase 2
Effects of Acipimox on Mitochondrial Function in Obesity
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01488409: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01488409 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488409, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of the study is to examine whether a medication called acipimox can improve your body's mitochondria. Mitochondria are the "power house" of the cell and make energy for your body. Obesity is associated with increased risk for developing diabetes. However, the investigators do not know how obesity leads to diabetes. Previous studies have shown levels of fat in the blood (free fatty acids or FFA) are higher in obesity, and elevated FFA can affect how our body uses glucose and responds to insulin. Recent studies have shown that changes in mitochondria may be involved in the development of diabetes and may be affected by FFA. The investigators propose to improve the function of mitochondria in obese people with pre-diabetes by treating with acipimox, a medication which decreases FFA. The investigators will use state of the art techniques to evaluate the mitochondria, including a new magnetic resonance imaging (MRI) technique to measure function of mitochondria in muscle.
Interventions
- DRUG Placebo
- DRUG Acipimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488409
The ClinicalTrials.gov registry entry for NCT01488409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01488409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01488409 about?
NCT01488409 is a clinical study titled "Effects of Acipimox on Mitochondrial Function in Obesity". The purpose of the study is to examine whether a medication called acipimox can improve your body's mitochondria. Mitochondria are the "power house" of the cell and make energy for your body. Obesity is associated with increased risk for developing diabetes. However, the investigators do not know h...
What is the current status of trial NCT01488409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2012-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01488409?
The interventions under investigation include: Placebo (DRUG), Acipimox (DRUG).
Who is sponsoring clinical trial NCT01488409?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.